Decision

Eli Lilly Canada Inc. v. Apotex Inc., 2018 FC 736 (Prasugrel*)

2018-07-13

Read full decision. Automatically generated summary:

In this PM(NOC) application, the Court concluded that the claims of the ‘644 Patent do relate to patentable subject matter; the Asserted Claims are invalid for obviousness; the ‘644 Patent makes a correct and full disclosure; and claim 29 is not overbroad.

Decision relates to:

  • T-1734-16 - ELI LILLY CANADA INC. ET AL v. APOTX INC. ET AL

 

Canadian Intellectual Property